Do you treat your epilepsy patients with generic drugs? What concerns might you still have about transitioning your patients?
Discuss these topics and more today during a Twitter chat hosted by Neurology Advisor editor Alicia Ciccone in partnership with the American Epilepsy Society (AES).
Now that the use of generic drugs in epilepsy is supported by both the FDA and AES, prescribing habits are bound to change. However, there are still outstanding concerns among both physicians and patients regarding bioequivalence, the risk of breakthrough seizures, and other adverse events.
Using AES president Dr Michael Privitera’s recent research on lamotrigine generics as a launching point, the tweet chat will cover topics including patient response to generics; variation in bioequivalence; challenges for physicians; and patient compliance.
Not sure how to participate? If you already have a Twitter account, follow these easy steps:
- Log-in to Twitter using Tweetchat.com or Tweetdeck.com
- Search for the hashtag #epilepsychat
- Follow along and add your opinion by using T1, T2, etc. for each discussion topic
- Don’t forget to include the #epilepsychat hashtag in all of your tweets!